UNSPSC 51291516: Nefazodone hydrochloride

This classification denotes a triazole, analgesic, and second-generation antidepressive agent with the molecular formula C25H32ClN5O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 27X63J94GR, chemically known as 3h-1,2,4-triazol-3-one, 2,4-dihydro-2-3-(4-(3-chlorophenyl)-1-piperazinyl)propyl)-5-ethyl-4-(2-phenoxyethyl)- but more generally known as nefazodone hydrochloride, which bears US NIH Compound Identifier 4449.

UNSPSC 51291516 Nefazodone hydrochloride, a Commodity-tier code, nominally names a specific antidepressant pharmaceutical but recent state and local activity under the code covers a broader range of pharmaceutical procurement — generic multi-source drugs, over-the-counter products, naloxone, and direct-to-manufacturer prescription fulfillment programs. State and local health departments, cooperative purchasing alliances, and county health agencies drive demand under this code. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, is actively procuring generic pharmaceuticals and OTC products through an RFP with an established multi-wholesaler distribution model; Seminole County, Florida issued an IFB for naloxone and drug deactivation systems; and the Texas Health and Human Services Commission released an RFI exploring direct-to-manufacturer prescription programs. These solicitations reflect state and local demand for cost-effective drug sourcing, emergency response pharmaceuticals, and alternative contracting models that bypass traditional pharmacy benefit managers and group purchasing organizations.

Recent activity concentrates in Minnesota, Florida, and Texas. The MMCAP RFP, due March 26, 2026, spans multiple participating states including Oregon and serves numerous state and local government facilities through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson); vendors must comply with cGMP certification, the Drug Supply Chain Security Act, and maintain $5 million commercial general liability coverage and $2 million network security and privacy liability coverage. Seminole County's IFB 60459723LAS, posted June 30, 2026 with a July 26, 2023 deadline, sought 1,900 units of naloxone and 800 safe drug deactivation systems annually on a two-year initial term with a one-year renewal option. The Texas HHS RFI HHS0017013, issued April 3, 2026, functions as market intelligence gathering to inform future formal procurement around direct-to-manufacturer relationships. These three solicitations suggest opportunity across health system procurement, emergency response supply chains, and pharmacy benefit program modernization.